Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II Controlled Study of PM01183 in Platinum-Resistant / Refractory Advanced Ovarian Cancer Patients

Next Previous
X
Search
Trial Profile

A phase II Controlled Study of PM01183 in Platinum-Resistant / Refractory Advanced Ovarian Cancer Patients

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 May 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lurbinectedin (Primary) ; Topotecan
  • Indications Ovarian cancer
  • Focus Proof of concept; Therapeutic Use
  • Sponsors PharmaMar

    • Most Recent Events

    • 29 Apr 2021 Results (N=244), Pharmacokinetic-pharmacodynamic analyses of pooled data from phase I studies A-0015 and A-005, and phase II studies B001, B-002, and B-0038 published in the Journal of Clinical Pharmacology
    • 09 Aug 2018 Results of pooled data from six phase I and three phase II trials with lurbinectedin, were published in the Clinical Pharmacokinetics.
    • 20 Mar 2017 Results published in the Annals of Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top